IDEAYA Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 124
- Market Cap
- $3.3B
- Website
- http://www.ideayabio.com
- Introduction
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by...
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 420
- Registration Number
- NCT05987332
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 82
- Registration Number
- NCT05907954
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 216
- Registration Number
- NCT05787587
- Locations
- 🇺🇸
The Angeles Clinic, Los Angeles, California, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 180
- Registration Number
- NCT04794699
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 341
- Registration Number
- NCT03947385
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸San Francisco Oncology Associates, San Francisco, California, United States
🇺🇸Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States